MISP

Across TCGA pan-cancer cohorts, MISP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MISP data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MISP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MISP expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and COAD are the cancer types where MISP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.908	0.537	<.001	52	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.495	.009	14	view →
COAD	DFS	Median	II,III,IV	1.000	0.909	.010	12	view →
CCRCC	DFS	Tertile	IV	0.108	1.000	.024	10	view →
LUAD	DFS	Median	II,III,IV	0.254	0.803	.022	7	view →
LSCC	DFS	Quartile	II,III,IV	0.790	1.000	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MISP–PDAC (DFS)

Open the PDAC breakdown →